Post-Debate Q&A: Should GLP-RA be First Line Therapy for Treatment of Obesity?

Forgot your password?

Select specialty

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

By Cedars Sinai FEATURING Kulmeet Sandhu, Martha Gulati

June 4, 2024

Feat. M. Koren

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

ASPC 2019 Congress on CVD Prevention

Robert Busch

Cardiometabolic Health Congress (CMHC)

Diana Isaacs

Michigan Medicine

Practical Ways to Achieve Targets in Diabetes Care

Diana Isaacs

Scripps Health

Houston Methodist

T. R. Mccarty

Scripps Health

McMaster University Department of Medicine

S. Boushahri, D. Lazzam, K. MacEachern

National Jewish Health

Login

Login

Join VuMedi

Post-Debate Q&A: Should GLP-RA be First Line Therapy for Treatment of Obesity?

Expert Insights on Adding a Non-Statin Lipid-Lowering Therapy in a R…

Initiating and Monitoring Patients on a Non-Statin Lipid-Lowering Th…

Recommended

Primer on Diabetes Management

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Labs to Check on Semaglutide or Tirzepatide

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Could GLP-1's be a 'Game Changer' For Weight Loss? Can it be a Safer…

Tirzepatide Updates

Weightloss in Menopause

Incretin-based Therapies in the Management of Obesity and its Comorb…

Metabolic Surgery vs. Pharmacotherapy for Treatment of Obesity

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

Tirzepatide for Type 2 Diabetes

The Differences Between the Products of GLP1's and GLP/GIPs

GLP-1 Hysteria

Endoscopic Weight Loss Therapies - A Paradigm Shift in the Treatment…

New Research: Side Effect of GLP1

Obesity: A Serious Cardiovascular Risk Factor? A Review of GLP-1 Rec…

Semaglutide: Where Are We Now and Where Are We Going?

GLP1 Agonists